Adoption of the PythiaAI™ Agentic LLM framework allowed for the Discovery of Novel Therapeutics in Record Time and Efficiency

HEREFORD, PA, UNITED STATES, September 5, 2024 /EINPresswire.com/ -- Today, StableBody Technologies and Quine Biologics announce the adoption of 20/15 Visioneers’ PythiaAI™ framework to accelerate their programs for designing stable antibodies.

PythiaAI™ is a first-of-a-kind Large Language Model (LLM) Agentic Framework focused on enriching R&D processes across a diverse set of scientific domains, from drug discovery to agriculture to materials and beyond. Working closely with Quine Biologics and StableBody, the 20/15 Visioneers team has trained PythiaAI™ to enable protein researchers with rapid i) discovery of novel emerging methods to guide protein engineering and ii) identification of disease indications.

"StableBody Technologies has built a leading-edge computational system for linear sequence of predicting enhanced stability and affinity in proteins. With PythiaAI™, we are now able to rapidly discover new hypotheses for protein stability, both in our experiments and in literature", says Harry Horn, CEO of StableBody Technologies “This addition has immediately solved the problem of searching the universe for new optimized proteins.”

"At Quine Biologics, our goal has always been to accelerate the development of highly specific and effective antibody therapeutics”, says Quine Biologics founder, Dr. Brett Spurrier. “By integrating PythiaAI™ into our Bespoke-A.B. design platform, we're able to leverage the advanced capabilities of LLMs to streamline the process of antibody design, from hypothesis generation to validation. This collaboration empowers us to enhance the stability and efficacy of our therapeutic antibodies more efficiently than ever before, pushing the boundaries of what's possible in protein engineering."

PythiaAI™ is an LLM-based software framework that is offered by the 20/15 Visioneers’ AI & GenAI Practice as a service. It can be configured, customized, and maintained to address the needs of a diverse range of R&D workflows. PythiaAI™ is unique in that it uses “agents” to work with any LLM as well as traditional software tools, to autonomously reason and mediate scientific knowledge and databases. The framework provides relevant and actionable insights to current R&D workflows. To ensure robustness, it is trained and deployed with the trifecta of human intuition and understanding, AI algorithms, and scientific knowledge.

"PythiaAI™ is a future-proof low-cost framework for R&D teams to take advantage of the power of LLMs. With StableBody Technologies and Quine Biologics, we have demonstrated its augmenting value and strengths in protein engineering.", says Dr. Raminderpal Singh, Global Head of AI & GenAI Practice, 20/15 Visioneers. "A biproduct of adopting PythiaAI™ is the overall reduction in technical debt to R&D teams, as 20/15 Visioneers can maintain and support the framework as part of its services offering.”

A demo of PythiaAI™ will be presented at the upcoming 20/15 Visioneers Webinar on October 1, 2024.

About 20/15 Visioneers
20/15 Visioneers is an in-demand science and technology management consulting, marketing, and staffing think-tank comprised of industry-hardened scientists (data, lab, computational) and informaticians. We are "Visioneering" the "Lab of the Future," including next-generation science and new modality challenges and problems.

Our domain expertise spans Life, Materials (including Consumer Packaged Goods (CPG), and AgriTech Science. Our talented team are proving know-how and expertise in scientific informatics strategy, chemistry and bioprocess development, lab automation, Cloud Labs, HTE (High Throughput Experimentation), NME (New Molecular Entity) Discovery, Computational Sciences, Cheminformatics, Bioinformatics, Microbiome, Multi-omics, New Modalities, and Information Technology.

About StableBody
is an expert in antibody thermodynamic stabilization and affinity optimization. The AffiBioTM software application optimizes recombinant scFv characteristics such as stability, affinity, solubility, and aggregation through the identification of amino acid positions targeted for modifications is guided by the evolutionary responses observed in protein databases. The StableBody Technologies approach to protein stabilization improvements is heuristic in nature, meaning StableBody Technologies its data builds on itself and significantly reduces design work.

About Quine
is an expert in structure-based de-novo antibody design therapies that retain therapeutic efficacy over time. The Bespoke-A.B. design platform that focuses on protein structure, automates and identifies the selection of antibody CDR sequences and conformations. The technology uses a denoising diffusion deep learning model resulting in a modeled 3D structural representation of the novel antibody-antigen complex. The technology creates new levels of unmatched specificity and high affinity for the antibody-antigen interaction. This result heralds a new era of tailored therapeutic and diagnostic agents.

SOURCE 20/15 Visioneers

John F. Conway
20/15 Visioneers
+1 610-906-6026
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.